HIV genes diversify in B cells

Current HIV Research

Volumn 6, Issue 1, 2008, Pages 10-18

  Balin, Samuel J ^a,b   Ross, Ted M ^c   Platt, Jeffrey L ^a,b   Cascalho, Marilia ^a,b  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

B cells; HIV; Quasi species

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; BETA 2 MICROGLOBULIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN; IMMUNOGLOBULIN H; MESSENGER RNA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANTIBIOTIC RESISTANCE; B LYMPHOCYTE; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; GENE FREQUENCY; GENETIC CODE; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGLOBULIN VARIABLE REGION; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN SYNTHESIS; REVIEW; SOMATIC HYPERMUTATION; VIRAL GENETICS; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS MUTATION; VIRUS RESISTANCE; ARTICLE; CELL CULTURE; CELL LINE; COMPLEMENTARITY DETERMINING REGION; DRUG EFFECT; ENVELOPE GENE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR EVOLUTION; MUTATION; PATHOPHYSIOLOGY; VIROLOGY;

B-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; COMPLEMENTARITY DETERMINING REGIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; EVOLUTION, MOLECULAR; GENES, ENV; HIV; HIV INFECTIONS; HUMANS; MUTATION; SEQUENCE ANALYSIS, DNA; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN; TRANSFECTION; VARIATION (GENETICS);

EID: 40449126766     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208783571919     Document Type: Review

References (40)

1. Mansky L, Temin H. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69(8): 5087-5094.
2. Richman D, Little S, Smith D, Wrin T, Petropoulos C, Wong J. HIV evolution of escape. Trans Am Clin Climatol Assoc 2004; 115: 289-303.
3. Smith RA, Loeb LA, Preston BD. Lethal mutagenesis of HIV. Virus Res 2005; 107(2): 215-28.
4. Bailey J, Blankson J, Wind-Rotolo M, Siliciano R. Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs. Curr Opin Immunol 2004; 16: 470-476.
5. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424(6944): 99-103.
6. Peng G, Lei K, Jin W, Greenwell-Wild T, Wahl S. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 2006; 203(1): 41-46.
7. Moir S, Lapointe R, Malaspina A, Ostrowski M, Cole C, Chun T, Adelsberger J, Baseler M, Hwu P, Fauci A. CD40-mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: Potential role of B lymphocytes as a viral reservoir. J Virol 1999; 73(10):7972-7980.
8. De Silva F, Venturini D, Wagner E, Shank P, Sharma S. CD4-independent infection of human B cells with HIV type 1: Detection of unintegrated viral DNA. AIDS Res Hum Retroviruses 2001; 17(17):1585-1598.
9. Wabl M, Burrows PD, von Gabain A, Steinberg C. Hypermutation at the immunoglobulin heavy chain locus in a pre-B-cell line. Proc Natl Acad Sci USA 1985; 82(2):479-482.
10. Drake J. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci 1993; 90:4171-4175.
11. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102(5): 553-563.
12. Suslov K. Does AID aid AIDS? Immunol Lett 2004; 91:1-2.
13. Pasqualucci L, Migliazza A, Fracchiolla N, William C, Neri A, Baldini L, Chaganti R, Klein U, Kuppers R, Rajewsky K, Dalla-Favera R. BCL-6 mutations in normal germinal center B cells: Evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci 1958; 95:11816-11821.
14. Wang C, Yang D, Wabl M. Directed molecular evolution by somatic hypermutation. Protein Eng Des Sel 2004; 17(9): 659-664.
15. Wang L, Tsien RY. Evolving proteins in mammalian cells using somatic hypermutation. Nat Protoc 2006; 1(3):1346-50.
16. Wabl M, Jack HM, Meyer J, Beck-Engeser G, von Borstel RC, Steinberg CM. Measurements of mutation rates in B lymphocytes. Immunol Rev 1987; 96: 91-107.
17. Bransteitter R, Pham P, Scharff MD, Goodman MF. Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc Natl Acad Sci USA 2003; 100(7): 4102-4107.
18. Chaudhuri J, Tian M, Khuong C, Chua K, Pinaud E, Alt FW. Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature 2003; 422(6933): 726-30.
19. Larijani M, Martin A. ssDNA structure and positional context of the target cytidine determine the enzymatic efficiency of AID. Mol Cell Biol 2007; 27(23): 8038-48.
20. Yang SY, Fugman SD, Gramlich HS, Schatz DG. Activation-induced cytidine deaminase-mediated sequence diversification is transiently targeted to newly integrated DNA substrates. J Biol Chem 2007; 282(35): 25308-13.
21. Bachl J, Olsson C, Chitkara N, Wabl M. The Ig mutator is dependent in the presence, position, and orientation of the large intron enhancer. Proc Natl Acad Sci USA 1998; 95(5): 2396-2399.
22. Wang CL, Harper RA, Wabl M. Genome-wide somatic hypermutation. Proc Natl Acad Sci U S A 2004; 101(19): 7352-6.
23. Yelamos J, Klix N, Goyenechea B, Lozano F, Chui YL, Gonzalez Fernandez A, Pannell R, Neuberger MS, Milstein C. Targeting of non-Ig sequences in place of the V segment by somatic hypermutation. Nature 1995; 376(6537): 225-229.
24. Burton D, Moore J. Why do we not have an HIV vaccine and how can we make one? Nature 1998; 4(5): 495-498.
25. Li Y, Kappes J, Conway J, Price R, Shaw G, Hahn B. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: Identification of replication-competent and -defective viral genomes. J Virol 1991; 65(8): 3973-3985.
26. Luciw P. Human immunodeficiency viruses and their replication. In: Fields BN, Knipe D, Howley P, editors. Fundamental Virology. Third ed. Philiadelphia: Lippincott - Raven Publishers; 1996. p. 845-916.
27. Bower J, Yang X, Sodroski J, Ross T. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol 2004; 78(9): 4710-4719.
28. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996; 271: 348-350.
29. Ramakrishna L, Anand KK, Mohankumar KM, Ranga U. Codon optimization of the tat amigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. J Virol 2004; 78(17): 9174-89.
30. Haas J, Park EC, Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996; 6(3); 315-24.
31. Young F, Ardman B, Shinkai Y, Lansford R, Blackwell TK, Mendelsohn M, Rolink A, Melchers F, Alt FW. Influence of immunoglobulin heavy- and light-chain expression on B-cell differentiation. Genes Dev 1994; 8(9): 1043-1057.
32. Gussow D, Rein R, Ginjaar I, Hochstenbach F, Seemann G, Kottman A, Ploegh HL. The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol 1987; 139(9): 3132-8.
33. Bransteitter R, Sneeden J, Allen S, Pham P, Goodman M. First AID (Activation-induced Cytidine Deaminase) is needed to produce high affinity isotype-switched antibodies. J Biol Chem 2006; 281(25): 16833-16836.
34. Casali P, Pal Z, Xu Z, Zan H. DNA Repair in antibody somatic hypermutation. Trends Immunol 2006; 27(7): 313-321.
35. Zan H, Wu X, Komori A, Holloman WK, Casali P: AID-dependent generation of resected double-strand DNA breaks and recruitment of Rad52/Rad51 in somatic hypermutation. Immunity 2003; 18: 727-738.
36. Maizels N. Immunoglobulin gene diversification. Annu Rev Genet 2005; 39: 23-46.
37. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-650.
38. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003; 114(1): 21-31.
39. Santa-Marta M, Aires da Silva F, Fonseca A, Rato S, Gonclaves J. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action. Mol Immunol 2007; 44: 583-590.
40. Bernardin F, Kong D, Peddada L, Baxer-Lowe L, Delwart E. Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes. J Virol 2005; 79(17): 11523-11528.